Ronald J Albers

This inventor holds 11 USPTO granted patents, plus 3 CIPO patents and 5 EPO patents. Top assignees: Signal Pharmaceuticals, Inc., Pharmacopeia Drug Discovery, Inc.. Active years: 2005-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ronald J Albers. Retrieved from https://idiyas.com/inventor/ronald-j-albers

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11

% Patents Active = 63.6

CIPO Patents = 3

EPO Patents = 5 (Patent Applications = 2)

Average Co-Inventor Count = 12.5

ph-index = 11

Forward Citations = 329(Granted Patents)

Location History:

La Jolla, CA (US) (2005 - 2007)
San Diego, CA (US) (2009 - 2013)

Company Filing History:

11 out of 169

Signal Pharmaceuticals, Inc.

patents

1 out of 52

Pharmacopeia Drug Discovery, Inc.

patents

where one patent can have more than one assignee

Years Active: 2005-2013

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8383634 - Methods of treatment using heteroaryl compounds and compositions thereof (2013-02-26),

2. 8372976 - Methods of treatment comprising the administration of heteroaryl compounds (2013-02-12),

3. 8101588 - Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith (2012-01-24),

4. 7981893 - Heteroaryl compounds, compositions thereof, and methods of treatment therewith (2011-07-19),

5. 7968556 - Heteroaryl compounds, compositions thereof, and methods of treatment therewith (2011-06-28),

6. 7723340 - Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith (2010-05-25),

7. 7521446 - Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith (2009-04-21),

8. 7220771 - Methods of using indazole derivatives as JNK inhibitors (2007-05-22),

9. 7211594 - Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith (2007-05-01),

10. 7208513 - Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith (2007-04-24),

11. 6897231 - Indazole derivatives as JNK inhibitors and compositions and methods related thereto (2005-05-24),

Title: The Innovative Contributions of Ronald J Albers

Introduction

Ronald J Albers is a prominent inventor based in San Diego, California. He has made significant contributions to the field of pharmaceuticals, particularly in the development of heteroaryl compounds. With a total of 11 patents to his name, Albers has established himself as a key figure in the innovation of methods for treating various medical conditions.

Latest Patents

Albers' latest patents focus on methods of treatment using heteroaryl compounds. One of his notable patents describes the administration of heteroaryl compounds for treating or preventing cancer, inflammatory conditions, immunological conditions, and metabolic conditions. The compounds are designed to inhibit kinase pathways, providing effective treatment options for patients in need.

Career Highlights

Throughout his career, Ronald J Albers has worked with several notable companies, including Signal Pharmaceuticals and Pharmacopeia Drug Discovery. His work in these organizations has contributed to advancements in drug discovery and development, particularly in the area of targeted therapies.

Collaborations

Albers has collaborated with esteemed colleagues such as John J Sapienza and Maria Mercedes Delgado Mederos. These partnerships have fostered innovation and have been instrumental in the progress of his research and development efforts.

Conclusion

Ronald J Albers is a distinguished inventor whose work has significantly impacted the pharmaceutical industry. His innovative approaches to treatment using heteroaryl compounds continue to pave the way for new therapeutic options.

Profile summary based on public USPTO records.